Secretary Wright visited PNNL's campus in Richland, Washington, late last year to meet with innovators in chemistry, biology, computing, and more.

The Genesis Mission will mobilize the Department of Energy’s 17 National Laboratories, industry, and academia to build an integrated discovery platform.

PNNL researchers are opening up a new front in the fight to stop viral pathogens, protecting people against multiple viruses.

Predicting how organisms’ characteristics respond to not only their genes, but also their environments (a nascent field called predictive phenomics), is extraordinarily challenging. Researchers at PNNL are using AI to tackle that challenge.

Researchers from PNNL and Parallel Works, Inc., applied machine learning methods to predict how much oxygen and nutrients are used by microorganisms in river sediments.

Lauren Charles, a chief data scientist at PNNL, showcased the vital research coming out of her program at The National Academies Forum workshop in Washington, D.C., January 15–16, 2025.

Over the next four years, PNNL and University of Arizona will develop open-source computational tools to better identify and characterize the viruses associated with the human microbiome.

Nine national laboratories, including PNNL, bring together over 1,000 scientists for a day to use AI to accelerate scientific discovery.

A cross-institutional team of scientists developed PeakQC, a new software tool for automated quality control of mass spectrometry data.

Neeraj Kumar discusses how AI can transform scientific research at the Platform for Advanced Scientific Computing Conference and Trillion Parameter Consortium European Workshop.

Ljiljana Paša-Tolić, a PNNL fellow, is the recipient of the 2024 International Mass Spectrometry Foundation’s Jochen Franzen Award. 

Vigorous exercise burns fat more in males than in females, but the benefits of exercise are broad for both sexes.

Scientists have learned more about how to protect the insulin-producing cells that die in patients with Type 1 diabetes.

Scientists have learned more about how drug resistance develops in patients with acute myeloid leukemia and how the process might be slowed.

The Rapid Assessment of Platform Technologies to Expedite Response project aims to prepare against future pandemics.

Data-driven autonomous technology to rapidly design and deliver antiviral interventions targeting SARS-CoV-2 to reduce drug discovery timeline and advance bio preparedness capabilities.

Parallel graph neural networks identify protein-ligand 3-D structural interactions to aid in protein function prediction and drug discovery.